Vaginal Gel Might Prevent HIV Hours After Exposure
Lab tests with monkeys look promising, study says (Source: Fertility News - Doctors Lounge)
Source: Fertility News - Doctors Lounge - March 12, 2014 Category: Reproduction Medicine Authors: webmaster at doctorslounge.com Tags: Gynecology, Infections, AIDS, Reproductive Medicine, Research, News, Source Type: news
CONRAD wins USAID Science and Technology Pioneers Prize for development of first vaginal gel proven to reduce HIV
(CONRAD) CONRAD, a leading reproductive health-research organization based at Eastern Virginia Medical School, today announced that they are a winner of the United States Agency for International Development Science and Technology Pioneers Prize for their work in developing tenofovir gel. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 29, 2014 Category: Infectious Diseases Source Type: news
Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
PARSIPPANY, N.J., and MONTREAL, May 1, 2013 -- (Healthcare Sales & Marketing Network) -- Actavis, Inc. (ACT), and Valeant Pharmaceuticals International, Inc. (VRX) (VRX) today announced that Actavis Specialty Brands (the "Company") has acquired ... Biopharmaceuticals, AcquisitionsValeant Pharmaceuticals, Actavis, Metronidazole (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 1, 2013 Category: Pharmaceuticals Source Type: news
Actavis buys antibiotic vaginal gel from Valeant for $55 million
(Reuters) - Generic drugmaker Actavis Inc bought the global rights to Canadian firm Valeant Pharmaceuticals International Inc's antibiotic vaginal gel for about $55 million. (Source: Reuters: Health)
Source: Reuters: Health - May 1, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Bee Venom Destroys HIV And Spares Surrounding Cells
Nanoparticles containing bee venom toxin melittin can destroy human immunodeficiency virus (HIV) while at the same time leaving surrounding cells unharmed, scientists from Washington University School of Medicine reported in the March 2013 issue of Antiviral Therapy. The researchers said that their finding is a major step toward creating a vaginal gel that can prevent HIV spread. HIV is the virus that causes AIDS. Joshua L... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 10, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news
Study of tenofovir vaginal gel shows daily dosing ineffective due to lack of adherence
(CONRAD) Researchers with the Microbicide Trials Network today announced results of the Vaginal and Oral Interventions to Control the Epidemic study at the Conference for Retroviruses and Opportunistic Infections in Atlanta, Georgia. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 4, 2013 Category: Global & Universal Source Type: news
The 30-year fight against HIV
Since its identification as the cause of Aids in 1984, scientists have made major advancements in tackling virus1984 Retrovirus is discovered as cause of Aids and later named human immunodeficiency virus or HIV.1986 Clinical trials show that HIV patients taking AZT (azidothymidine), an antiretroviral drug initially developed as a cancer therapy, were living longer than those who did not. AZT is shown to manage, but not cure, HIV and reduce the rates of mother-to-child infection in pregnancy.1987 The US FDA approves AZT as the first antiretroviral to be used as a treatment for Aids.1995 Jeff Getty, Aids activist, becomes th...
Source: Guardian Unlimited Science - March 3, 2013 Category: Science Authors: Caroline Davies Tags: The Guardian News Health Medical research Aids and HIV Society Source Type: news
Tenofovir Gel Wins Out In Drug Absorption Study, But HIV Prevention Trials Say Differently
A novel head-to-head study looking at differences in how the antiretroviral (ARV) drug tenofovir gets absorbed in the body as either an oral tablet or a vaginal gel found tenofovir gel can achieve substantially higher concentrations of active drug in vaginal tissue than the oral tablet, suggesting that tenofovir gel should be highly effective in protecting women against HIV transmitted through vaginal sex... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 1, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news
Tenofovir gel wins out in drug absorption study, but HIV prevention trials say differently
(Microbicide Trials Network) A study looking at how the body absorbs the antiretroviral drug tenofovir as either an oral tablet or a vaginal gel found the gel achieves much higher concentrations of active drug in vaginal tissue than the tablet, suggesting it to be highly effective in protecting against HIV through vaginal sex. But results of HIV prevention trials have shown differently, leading researchers to conclude that effectiveness of tenofovir products depends not just on tissue concentrations. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 30, 2013 Category: Infectious Diseases Source Type: news
